Clinical Trial

Foundation for Sarcoidosis Research (FSR) receives confirmation from the Department of Labor (DOL) ensuring patient access to FMLA for participation in clinical trials

CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request…

1 month ago

Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024

Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data…

1 month ago

Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc…

1 month ago

Junshi Biosciences Announces UK MHRA Approval for Marketing of Toripalimab

SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

1 month ago

Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of Urologic Oncology

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the…

1 month ago

Eagle Announces Update on Delisting from Nasdaq and SEC Deregistration

WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”)…

1 month ago

Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…

1 month ago

Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon

50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the…

1 month ago